ClinicalTrials.gg
TerminatedNCT03430063Updated Nov 3, 2022Results posted

A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

A Phase 2 interventional study of SDREGN2810 and SDREGN2810/ipi in Advanced Non-Small Cell Lung Carcinoma, sponsored by Regeneron Pharmaceuticals. Terminated at 31 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-03.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 18 open to participants now, 22 under way, 3 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.

Enrollment
23rd of 29
28 · median 61
Started
2018
with 3 others
Phase 2
19 of 29
13 open now
Registered
3rd of 29
by date
Lead sponsor
7 of 29
Regeneron Pharmaceuticals

Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 23rd largest by enrollment, is one of 4 that started in 2018, is one of 19 in phase 2, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

18 of the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The primary objective of the study is to compare the objective response rate (ORR) of high dose cemiplimab (HDREGN2810) and standard dose cemiplimab plus ipilimumab combination therapy (SDREGN2810/ipi) to the ORR of standard dose cemiplimab (SDREGN2810) in the second-line treatment of patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC), in patients whose tumors express programmed cell death ligand 1 (PD-L1) in \<50% of tumor cells.

03

Conditions studied

  • Advanced Non-Small Cell Lung Carcinoma

Keywords

  • Advanced non-squamous NSCLC
  • Advanced squamous NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Patients with or cytologically documented squamous or non-squamous NSCLC who either have stage IIIb or stage IIIc disease who are not candidates for treatment with definitive concurrent chemo-radiation or have stage IV disease. Patients must have PD after receiving one treatment for advanced NSCLC.
  2. Availability of an archival or on-study obtained formalin-fixed, paraffin-embedded tumor tissue sample
  3. Biopsy evaluable for expression of as determined by a PD-L1 Immunohistochemistry (IHC) pharma diagnostic test (pharmDx) assay performed by a central laboratory
  4. At least 1 radiographically measureable lesion by computed tomography (CT) per 1.1 criteria
  5. (ECOG) performance status of ≤1

Key Exclusion Criteria:

  1. Patients who have never smoked, defined as smoking ≤100 cigarettes in a lifetime
  2. Active or untreated or spinal cord compression
  3. Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or C-ros oncogene receptor tyrosine kinase (ROS1) fusions
  4. Encephalitis, meningitis, or uncontrolled seizures in the year prior to randomization
  5. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), or active, noninfectious pneumonitis that required immune-suppressive doses of to assist with management, or of pneumonitis within the last 5 years
  6. Ongoing or recent evidence of significant disease that required treatment with systemic treatments, which may suggest a risk of immunerelated treatment-emergent adverse events (irTEAEs)
  7. Patients with a condition requiring corticosteroid therapy (>10 mg prednisone/day or equivalent) within 14 days of randomization

Note: Other protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    SDREGN2810

    Drug: SDREGN2810

  • Experimental
    SDREGN2810/ipi

    Drug: SDREGN2810/ipi

  • Experimental
    HDREGN2810

    Drug: HDREGN2810

Interventions

  • Standard dose intravenous (IV) infusion

    Also known as: REGN2810, cemiplimab

  • DrugSDREGN2810/ipi

    Drug page: Cemiplimab

    Combination therapy dose IV

    Also known as: REGN2810, cemiplimab, ipilimumab

  • High dose IV

    Also known as: REGN2810, cemiplimab

This study also gives Ipilimumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) in Participants Whose Tumors Express Programmed Cell Death Ligand 1 (PD-L1) in <50% of Tumor Cells

    ORR was defined as the number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of participants in the efficacy analysis set. BOR was defined as the best response recorded, as determined by a blinded Independent Review Committee (IRC) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) between the date of randomization and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever came first. CR was defined as the disappearance of all target lesions (Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm \[\<1 cm\]). PR was defined as having at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From date of randomization up to 41 months

Secondary outcomes

  1. Overall Response Rate

    Overall Response Rate was defined as the number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of participants in the efficacy analysis set. BOR was defined as the best response recorded, as determined by a blinded Independent Review Committee (IRC) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) between the date of randomization and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever came first. CR was defined as the disappearance of all target lesions (Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm \[\<1 cm\]). PR was defined as having at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From date of randomization up to 41 months

  2. Overall Survival (OS) in Participants With Tumor PD-L1 Expression Levels <50% of Tumor Cells

    OS was defined as the time from randomization to the date of death due to any cause. A participant who lost to follow-up was censored at the last date that the participant was known to be alive. OS was measured using Kaplan-Meier method.

    Time frame: Time from randomization to the date of death (up to 41 months)

  3. Progression Free Survival (PFS) in Participants With Tumor PD-L1 Expression Levels <50% of Tumor Cells

    PFS was defined as the time from randomization to the date of the first documented tumor progression, as determined by the IRC (based on RECIST 1.1 assessments) or death due to any cause, whichever occurred earlier. PFS was measured using Kaplan-Meier method.

    Time frame: Time from randomization up to the date of the first documented tumor progression or death (up to 41 months)

  4. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Resulting in Death

    Adverse event (AE): any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE: AE with onset after start of treatment or with onset date before the treatment start date but worsening after the treatment start date. TEAEs included both serious and non-serious TEAEs. Number of participants with TEAEs, Serious TEAEs and TEAEs leading to death were reported.

    Time frame: Up to 41 months

  5. Number of Participants With Laboratory Test Abnormalities of Grade 2 or Higher Severity Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grading System

    The laboratory measurements included hematology, chemistry, electrolytes and liver function. NCI-CTCAE was graded according to the following scale: Grade 1 (Mild): Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2 (Moderate): Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL); Grade 3 (Severe): Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4 (Life-threatening): Life-threatening consequences; urgent intervention indicated; Grade 5 (Death): Death related to AE.

    Time frame: Up to 41 months

07

Results

Posted Nov 3, 2022
Limitations and caveats
All participants' tumors had PD-L1 expression levels of \<50% at baseline. Therefore, the results do not present efficacy for participants with PD-L1 expression levels of ≥50% of tumor cells versus all participants.

Participant flow

Due to early enrollment cessation, only 28 participants were randomized and 27 participants received study treatment in this study. One participant was randomized but not treated.

Participant flow — Overall Study
MilestoneCemiplimab 350 mg Q3WCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 1050 mg Q3W
Started8119
Treated8118
Completed031
Not completed888
Withdrew: Adverse event010
Withdrew: Death323
Withdrew: Lost to follow-up010
Withdrew: Withdrawal by subject001
Withdrew: Withdrawal of consent312
Withdrew: Progressive disease121
Withdrew: Other un-specified110
Withdrew: Randomized, but never treated001

Outcome measures

PrimaryObjective Response Rate (ORR) in Participants Whose Tumors Express Programmed Cell Death Ligand 1 (PD-L1) in <50% of Tumor Cells

ORR was defined as the number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of participants in the efficacy analysis set. BOR was defined as the best response recorded, as determined by a blinded Independent Review Committee (IRC) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) between the date of randomization and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever came first. CR was defined as the disappearance of all target lesions (Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm \[\<1 cm\]). PR was defined as having at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From date of randomization up to 41 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) in Participants Whose Tumors Express Programmed Cell Death Ligand 1 (PD-L1) in <50% of Tumor Cells
Percentage of participantsCemiplimab 350 mg Q3WCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 1050 mg Q3W
Objective Response Rate (ORR) in Participants Whose Tumors Express Programmed Cell Death Ligand 1 (PD-L1) in <50% of Tumor Cells0 (0.0 to 36.9)45.5 (16.7 to 76.6)0 (0.0 to 36.9)
SecondaryOverall Response Rate

Overall Response Rate was defined as the number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of participants in the efficacy analysis set. BOR was defined as the best response recorded, as determined by a blinded Independent Review Committee (IRC) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) between the date of randomization and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever came first. CR was defined as the disappearance of all target lesions (Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm \[\<1 cm\]). PR was defined as having at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From date of randomization up to 41 months
Reported as:
Number · Percentage of participants
Overall Response Rate
Percentage of participantsCemiplimab 350 mg Q3WCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 1050 mg Q3W
Complete Response000
Partial Response045.50
SecondaryOverall Survival (OS) in Participants With Tumor PD-L1 Expression Levels <50% of Tumor Cells

OS was defined as the time from randomization to the date of death due to any cause. A participant who lost to follow-up was censored at the last date that the participant was known to be alive. OS was measured using Kaplan-Meier method.

Time frame:
Time from randomization to the date of death (up to 41 months)
Reported as:
Median · Months
Overall Survival (OS) in Participants With Tumor PD-L1 Expression Levels <50% of Tumor Cells
MonthsCemiplimab 350 mg Q3WCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 1050 mg Q3W
Overall Survival (OS) in Participants With Tumor PD-L1 Expression Levels <50% of Tumor Cells5.1 (1.7 to NA)NA (2.2 to NA)8.4 (1.4 to NA)
SecondaryProgression Free Survival (PFS) in Participants With Tumor PD-L1 Expression Levels <50% of Tumor Cells

PFS was defined as the time from randomization to the date of the first documented tumor progression, as determined by the IRC (based on RECIST 1.1 assessments) or death due to any cause, whichever occurred earlier. PFS was measured using Kaplan-Meier method.

Time frame:
Time from randomization up to the date of the first documented tumor progression or death (up to 41 months)
Reported as:
Median · Months
Progression Free Survival (PFS) in Participants With Tumor PD-L1 Expression Levels <50% of Tumor Cells
MonthsCemiplimab 350 mg Q3WCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 1050 mg Q3W
Progression Free Survival (PFS) in Participants With Tumor PD-L1 Expression Levels <50% of Tumor Cells2.0 (0.7 to 8.3)20.8 (1.2 to NA)1.8 (1.1 to 2.2)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Resulting in Death

Adverse event (AE): any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE: AE with onset after start of treatment or with onset date before the treatment start date but worsening after the treatment start date. TEAEs included both serious and non-serious TEAEs. Number of participants with TEAEs, Serious TEAEs and TEAEs leading to death were reported.

Time frame:
Up to 41 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Resulting in Death
ParticipantsCemiplimab 350 mg Q3WCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 1050 mg Q3W
Participants with any TEAE7118
Participants with any serious TEAE174
Participants with any TEAE resulting in death021
SecondaryNumber of Participants With Laboratory Test Abnormalities of Grade 2 or Higher Severity Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grading System

The laboratory measurements included hematology, chemistry, electrolytes and liver function. NCI-CTCAE was graded according to the following scale: Grade 1 (Mild): Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2 (Moderate): Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL); Grade 3 (Severe): Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4 (Life-threatening): Life-threatening consequences; urgent intervention indicated; Grade 5 (Death): Death related to AE.

Time frame:
Up to 41 months
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities of Grade 2 or Higher Severity Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grading System
ParticipantsCemiplimab 350 mg Q3WCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 1050 mg Q3W
Hematology235
Electrolytes331
Liver Function231
Chemistry110

Adverse events

Collected over From first dose up to 41 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cemiplimab 350 mg Q3W3/8 (37.5%)1/8 (12.5%)7/8 (87.5%)
Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W3/11 (27.3%)7/11 (63.6%)11/11 (100%)
Cemiplimab 1050 mg Q3W4/8 (50%)4/8 (50%)8/8 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventCemiplimab 350 mg Q3WCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 1050 mg Q3W
PneumoniaInfections and infestations0/83/110/8
Brain stem embolismNervous system disorders0/80/111/8
Cerebrovascular accidentNervous system disorders0/80/111/8
HemiparesisNervous system disorders0/80/111/8
BradypnoeaRespiratory, thoracic and mediastinal disorders0/80/111/8
DyspnoeaRespiratory, thoracic and mediastinal disorders0/80/111/8
Febrile neutropeniaBlood and lymphatic system disorders0/80/111/8
Acute myocardial infarctionCardiac disorders0/80/111/8
Angina unstableCardiac disorders0/80/111/8
HyperkalaemiaMetabolism and nutrition disorders1/80/110/8
Most frequent other events
Showing 10 of 112
Most frequent other events
EventCemiplimab 350 mg Q3WCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 1050 mg Q3W
Decreased appetiteMetabolism and nutrition disorders4/83/113/8
ConstipationGastrointestinal disorders3/82/111/8
VomitingGastrointestinal disorders3/82/110/8
HypothyroidismEndocrine disorders0/83/110/8
DiarrhoeaGastrointestinal disorders2/83/111/8
PneumoniaInfections and infestations0/83/110/8
ArthralgiaMusculoskeletal and connective tissue disorders1/83/110/8
Back painMusculoskeletal and connective tissue disorders1/83/111/8
DyspnoeaRespiratory, thoracic and mediastinal disorders2/83/112/8
RashSkin and subcutaneous tissue disorders1/83/111/8

Baseline characteristics

Safety analysis set (SAF) included all randomized participants who received any study drug; it is based on the treatment received (as treated).

Age, Continuous
Age, Continuous(years)Cemiplimab 350 mg Q3WCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 1050 mg Q3WTotal
Mean62.4 ± 7.9168.5 ± 8.7268.1 ± 12.0866.6 ± 9.65
Sex: Female, Male
Sex: Female, Male(Participants)Cemiplimab 350 mg Q3WCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 1050 mg Q3WTotal
Female2417
Male67720
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cemiplimab 350 mg Q3WCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 1050 mg Q3WTotal
Hispanic or Latino0000
Not Hispanic or Latino67619
Unknown or Not Reported2428
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cemiplimab 350 mg Q3WCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 1050 mg Q3WTotal
American Indian or Alaska Native0000
Asian63312
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0538
More than one race0000
Unknown or Not Reported2327
Number of Participants with PD-L1 Tumor Expression Levels of ≥50% of Tumor Cells
Number of Participants with PD-L1 Tumor Expression Levels of ≥50% of Tumor Cells(Participants)Cemiplimab 350 mg Q3WCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 1050 mg Q3WTotal
Count of participants0000
08

Study locations

31 sites
  • Regeneron Research Site
    Phoenix, Arizona 85054, United States
  • Regeneron Research Site
    Los Angeles, California 90033, United States
  • Regeneron Research Site
    Whittier, California 90603, United States
  • Regeneron Research Site
    Scarborough, Maine 04074, United States
  • Regeneron Research Site
    Canton, Ohio 44708, United States
  • Regeneron Research Site
    Massillon, Ohio 44646, United States
  • Regeneron Research Site
    Herstal, 4040, Belgium
  • Regeneron Research Site
    Yvoir, 5530, Belgium
  • Regeneron Research Site
    Poitiers, 86021, France
  • Regeneron Research Site
    Rennes, 35033, France
  • Regeneron Research Site
    Saint-Mandé, 94160, France
  • Regeneron Research Site
    Gauting, 82131, Germany
  • Regeneron Research Site
    Incheon, 22332, Korea, Republic of
  • Regeneron Research Site
    Jeongnam, 58128, Korea, Republic of
  • Regeneron Research Site
    Seongnam, 463707, Korea, Republic of
  • Regeneron Research Site
    Seoul, 03722, Korea, Republic of
  • Regeneron Research Site
    Seoul, 05505, Korea, Republic of
  • Regeneron Research Site
    Seoul, 06591, Korea, Republic of
  • Regeneron Research Site
    Suwon, 16247, Korea, Republic of
  • Regeneron Research Site
    Gdynia, 81519, Poland
  • Regeneron Research Site
    Grudziądz, 86300, Poland
  • Regeneron Research Site
    Otwock, 05400, Poland
  • Regeneron Research Site
    Badalona, 8911, Spain
  • Regeneron Research Site
    Barcelona, 08025, Spain
  • Regeneron Research Site
    Madrid, 28046, Spain
  • Regeneron Research Site
    Málaga, 29010, Spain
  • Regeneron Research Site
    Zaragoza, 50009, Spain
  • Regeneron Research Site
    Taipei, 11217, Taiwan
  • Regeneron Research Site
    London, W1G6AD, United Kingdom
  • Regeneron Research Site
    Manchester, M20 4BX, United Kingdom
  • Regeneron Research Site
    Plymouth, PL68DH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Oct 2021, 40 months.

Results were first posted in Nov 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2018
First posted
Feb 12, 2018
StartActual
May 29, 2018
Primary completionActual
Oct 27, 2021
CompletionActual
Oct 27, 2021
Results first posted
Nov 3, 2022
Last update
Nov 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03430063
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Feb 12, 2018
Start date
May 29, 2018
Primary completion
Oct 27, 2021
Completion
Oct 27, 2021
Results posted
Nov 3, 2022
Last update
Nov 3, 2022

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion